MaxQ Medical Prostate Platform Lands $31.5M Series A Led by Olympus

MaxQ Medical has closed a $31.5m Series A round. The funding will push the MaxQ Medical prostate platform toward broader clinical use. The system pairs ultrasound imaging with targeted therapy for prostate care in one transurethral procedure.

Olympus Innovation Ventures, Atlantic Blue Ventures, and S3 Ventures co-led the round. Existing investor Hillside Capital joined too. The California-headquartered company plans to grow its team. It also plans to advance clinical programmes around the platform.

The first target for the MaxQ Medical prostate platform is benign prostate hyperplasia (BPH). BPH makes urinating difficult for many men. The Urology Care Foundation estimates 40 million US men have BPH, also known as enlarged prostate.

Inside the MaxQ Medical prostate platform

The MaxQ Medical prostate platform pairs advanced imaging with tissue-selective therapy. It runs in one transurethral procedure. The design gives urologists a direct view inside the prostate. Then it lets them treat what they see. That avoids the anatomic limits of methods that work from outside.

The design also aims to preserve the urethra. The company said it aims to cut side effects that "remain common concerns with current treatment options" for prostate care. Those side effects include injury, swelling and bleeding, and impact on sexual functions.

Where MaxQ fits vs. TURP and Rezūm

The historical surgical gold standard for BPH is transurethral resection of the prostate (TURP). A TURP procedure inserts a special instrument through the urethra. The surgeon then removes excess inner prostate tissue. That widens the urinary channel.

Minimally invasive options exist too. Boston Scientific's Rezūm therapy uses water vapour. It shrinks excess prostate tissue volume. That is a main tMIS alternative.

MaxQ pitches its platform as a middle path. The aim is durability close to gold standard resection. But the side-effect profile stays lighter.

CEO on the funding rationale

MaxQ Medical CEO Amir Tehrani framed the raise as a patient-choice fix.

Tehrani said: "Men with prostate disease have had to choose between treatments that don't do enough and treatments that come with consequential trade-offs and side effects. The MaxQ system is designed to offer the durability of gold standard resective therapies with side effects more comparable to transurethral minimally invasive surgery (tMIS) solutions."

Tehrani added: "This funding lets us continue the clinical evaluations already underway and move closer to giving physicians and their patients a better option."

Roadmap beyond BPH

The MaxQ Medical prostate platform is not stopping at BPH. The company plans to expand into focal therapy for prostate cancer. Longer term, it also wants to expand into broader prostate diagnostics. That includes biopsy and tumour mapping.

Why the MaxQ Medical prostate platform matters now

BPH is one of the highest volume urological workloads. The current menu forces trade-offs. TURP gives durability. But it carries surgical risks. Minimally invasive tools like Rezūm cut those risks. But they can trade off durability.

A tissue-selective, imaging-guided transurethral approach could shift that. It could also open doors to focal prostate cancer therapy. For urology, MedTech investment, and hospital procurement teams, the MaxQ Medical prostate platform is worth watching. Coverage on Medigear.uk tracks its clinical steps.

Source: Originating coverage based on Medical Device Network reporting by Ross Law, August 20, 2026, on MaxQ Medical's $31.5m Series A financing round to advance its ultrasound-imaging and tissue-selective prostate care platform. URL: https://www.medicaldevice-network.com/